Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial - Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030574

Enrollment

106

Registered

2018-01-01

Start date

2018-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological surgery patiets

Interventions

Administration of 5mg of olanzapine before 1 hour of admission of operating room Administration of placebo before 1 hour of admission of operating room

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: gynecologic surgical patients no smoking patients

Exclusion criteria

Exclusion criteria: the contraindication

Design outcomes

Primary

Measure	Time frame
The incidence of not PONV after 24 hours after operation	—

Secondary

Measure	Time frame
The incidence of PONV every hour The incidence of no nausea and no vomiting every hour The severity of nausea every hour The frequency of using anti-emetic agents every hour	—

Countries

Japan

Contacts

Public ContactToshiyuki Kuriyama

Wakayama Medical University Department of Anesthesiology

kuriyama@xa2.so-net.ne.jp073-441-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026